Lori Hazlehurst
Affiliations: | Biology (Cell Biology, Microbiology, Molecular Biology) | University of South Florida, Tampa, FL, United States |
Area:
Oncology, Cell Biology, PharmacologyGoogle:
"Lori Hazlehurst"Children
Sign in to add trainee| Nadine N. Bewry | grad student | 2009 | University of South Florida |
| Anthony W. Gebhard | grad student | 2013 | University of South Florida |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Wang L, Yi W, Ma L, et al. (2023) Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling. Cancers. 15 |
| Jones C, Dziadowicz S, Suite S, et al. (2022) Emergence of Resistance to MTI-101 Selects for a MET Genotype and Phenotype in EGFR Driven PC-9 and PTEN Deleted H446 Lung Cancer Cell Lines. Cancers. 14 |
| Dziadowicz SA, Wang L, Akhter H, et al. (2022) Bone Marrow Stroma-Induced Transcriptome and Regulome Signatures of Multiple Myeloma. Cancers. 14 |
| Jain P, Badger DB, Liang Y, et al. (2020) Bioactivity improvement via display of the hydrophobic core of HYD1 in a cyclic β-hairpin-like scaffold, MTI-101. Peptide Science (Hoboken, N.J.). 113: e24199 |
| Chen WC, Hu G, Hazlehurst LA. (2020) Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors. Current Opinion in Pharmacology. 54: 36-43 |
| Freeman S, Elzamzamy O, Geldenhuys W, et al. (2020) CLIC1 is an Attractive Candidate for the Initial Binding Target of the Novel Peptide MTI‐101 The Faseb Journal. 34: 1-1 |
| Toth RK, Tran JD, Muldong MT, et al. (2019) Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC. American Journal of Clinical and Experimental Urology. 7: 297-312 |
| Chen W, Hazlehurst L. (2019) Abstract 852: Determining the roles of ERO1-alpha and ERO1-beta in progression of multiple myeloma and drug resistance Cancer Research |
| Sweet K, Hazlehurst L, Sahakian E, et al. (2018) A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leukemia Research. 74: 89-96 |
| von Roemeling CA, Caulfield TR, Marlow L, et al. (2018) Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy. Oncotarget. 9: 3-20 |